Product Pathways - PI3K / Akt Signaling
SignalSilence® Tuberin/TSC2 siRNA II #6548
|6548S||300 µl (3 nmol)||---||In Stock||---|
|6548||carrier free and custom formulation / quantity||email request|
This item is packaged to order. Please allow two to three days for your order to be processed and shipped.
Already purchased this product? Write a Review.
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 (-) or SignalSilence® Tuberin/TSC2 siRNA I #6476 or SignalSilence® Tuberin/TSC2 siRNA II (+), using Tuberin/TSC2 (28A7) Rabbit mAb #3635 and α-Tubulin (11H10) Rabbit mAb #2125. Tuberin/TSC2 (28A7) Rabbit mAb confirms silencing of Tuberin/TSC2 expression and α-Tubulin (11H10) Rabbit mAb is used to control for loading and specificity of Tuberin/TSC2 siRNA.
SignalSilence® Tuberin/TSC2 siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit tuberin/TSC2 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions For Use
CST recommends transfection with 100 nM Tuberin/TSC2 siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
Tuberin is a product of the TSC2 tumor suppressor gene and an important regulator of cell proliferation and tumor development (1). Mutations in either TSC2 or the related TSC1 (hamartin) gene cause tuberous sclerosis complex (TSC), an autosomal dominant disorder characterized by development of multiple, widespread non-malignant tumors (2). Tuberin is directly phosphorylated at Thr1462 by Akt/PKB (3). Phosphorylation at Thr1462 and Tyr1571 regulates tuberin-hamartin complexes and tuberin activity (3-5). In addition, tuberin inhibits the mammalian target of rapamycin (mTOR), which promotes inhibition of p70 S6 kinase, activation of eukaryotic initiation factor 4E binding protein 1 (4E-BP1, an inhibitor of translation initiation), and eventual inhibition of translation (3,6,7).
- Soucek, T. et al. (1998) Proc. Natl. Acad. Sci. USA 95, 15653-15658.
- Sparagana, S.P. and Roach, E.S. (2000) Curr. Opin. Neurol. 13, 115-119.
- Manning, B. D. et al. (2002) Mol. Cell 10, 151-161.
- Aicher, L. D. et al. (2001) J. Biol. Chem. 276, 21017-21021.
- Dan, H. C. et al. (2002) J. Biol. Chem. 277, 35364-35370.
- Goncharova, E.A. et al. (2002) J. Biol. Chem. 277, 30958-30967.
- Inoki, K. et al. (2002) Nat. Cell Biol. 4, 648-657.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
SignalSilence® is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.